Marksans Pharma - Public Comps and Valuation Multiples

Marksans Pharma Overview

About Marksans Pharma

Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.

Founded

1992

HQ

Employees

1.3K+

Website

marksanspharma.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue $295M

Last FY EBITDA $67.6M

EV

$867M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Marksans Pharma Financials

See Marksans Pharma valuation multiples based on analyst estimates

Marksans Pharma P&L

In the most recent fiscal year, Marksans Pharma reported revenue of $295M and EBITDA of $67.6M.

Marksans Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Marksans Pharma valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$295M	XXX	XXX	XXX
Gross Profit	XXX	$156M	XXX	XXX	XXX
Gross Margin	XXX	53%	XXX	XXX	XXX
EBITDA	XXX	$67.6M	XXX	XXX	XXX
EBITDA Margin	XXX	23%	XXX	XXX	XXX
EBIT	XXX	$51.4M	XXX	XXX	XXX
EBIT Margin	XXX	17%	XXX	XXX	XXX
Net Profit	XXX	$42.9M	XXX	XXX	XXX
Net Margin	XXX	15%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Marksans Pharma including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Marksans Pharma achieved $295M in revenue and $67.6M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$295M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$156M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	53.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$67.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	22.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$51.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	17.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$42.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	14.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Marksans Pharma

This financial data table provides comprehensive performance metrics for Marksans Pharma, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Marksans Pharma reported $295M in total revenue.
Fiscal year EBITDA was $67.6M.
The company maintained a gross profit margin of 53.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 22.9%.
Net profit margin reached 14.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Marksans Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Marksans Pharma Stock Performance

Marksans Pharma has current market cap of INR 80.7B (or $910M), and EV of INR 76.9B (or $867M).

Market Cap Evolution

Marksans Pharma Stock Data

As of October 17, 2025, Marksans Pharma's stock price is INR 178 (or $2).

See Marksans Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$867M	$910M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Marksans Pharma Valuation Multiples

Marksans Pharma's trades at 2.9x EV/Revenue multiple, and 12.8x EV/EBITDA.

See valuation multiples for Marksans Pharma and 15K+ public comps

Marksans Pharma Financial Valuation Multiples

As of October 17, 2025, Marksans Pharma has market cap of $910M and EV of $867M.

Equity research analysts estimate Marksans Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Marksans Pharma's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$910M	XXX	$910M	XXX	XXX	XXX
EV (current)	$867M	XXX	$867M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	2.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	12.8x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	16.9x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	21.2x	XXX	XXX	XXX
EV/FCF	n/a	XXX	227.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Marksans Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Marksans Pharma Margins & Growth Rates

Marksans Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Marksans Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Marksans Pharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Marksans Pharma and other 15K+ public comps

Marksans Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	23%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	36%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial